Alfa Cytology Launches Hu-Immune Trademark Platform to Facilitate Immunotherapy Candidate Screening and Preclinical Studies

Alfa Cytology launched the Hu-Immune Trademark platform to provide humanized mouse models and preclinical services for efficient immunotherapy screening and accelerated R&D.
New York, USA - January 28, 2026 - With the rapid development of immune checkpoint inhibitors, bispecific antibodies, and cell therapies, research and development teams are facing increasing challenges during candidate screening and preclinical studies. Traditional mouse models have limited ability to reflect the human immune response, often resulting in safety or efficacy issues being identified at the preclinical stage. By reconstructing a functional human immune system in mice, Alfa Cytology's Hu-Immune Trademark platform [https://www.hu-immune.com/platform.html] generates in vivo data relevant to preclinical research, helping improve the efficiency and predictability of immunotherapy development.

Image: https://www.globalnewslines.com/uploads/2025/08/a17b7ed1da71cb24749496712dec493d.jpg

Over the years, research teams and biotech companies have been confronted with a series of persistent technical challenges, including low screening efficiency, limited predictability of immune responses in vivo , and excessive uncertainty in the preclinical development process. These challenges have slowed the progress of immunotherapy research. The Hu-Immune Trademark platform solves these issues by offering an integrated workflow that spans model construction, candidate screening, and in vivo efficacy evaluation, providing preclinical drug screening services [https://www.hu-immune.com/preclinical-services.html] to facilitate faster and more accurate decision-making.

The platform provides two types of humanized mouse models, huPBMC and huHSC, to meet different preclinical research needs. The huPBMC model is suitable for conducting short-term and rapid candidate screening and can provide strong results for immune response detection. The huHSC model supports the reconstruction of a multi-lineage human immune system and is applicable to longer-term efficacy assessment and mechanism studies.

Researchers can formulate experimental strategies based on specific biological issues, such as guiding immune cells to the tumor site or assessing the activation status of multiple immune signaling pathways. Additional services, including functional optimization, data verification, and structural integrity assessment, help ensure reproducibility and scientific validity, providing a solid data foundation for subsequent preclinical research and drug development.

"During the development of immunotherapy, the early in vivo experimental data are of great significance, as even the slightest difference could have an impact on the results of the preclinical trials," said a representative from Alfa Cytology. "By integrating model construction, in vivo evaluation, and data analysis, the Hu-Immune Trademark platform enables systematic assessment of key variables, supporting more predictable and reproducible preclinical studies."

About Alfa Cytology

Alfa Cytology specializes in humanized immune system mouse models and preclinical immunotherapy research services. Through the Hu-Immune Trademark platform, the company provides a complete research process from model construction, candidate drug screening, to in vivo efficacy verification, and maintains long-term cooperation with academic institutions, biotechnology companies, and scientific research organizations to continuously promote the efficiency of immunotherapy research and development and the ability of preclinical translation.
Media Contact
Company Name: Alfa Cytology
Contact Person: Toya Davis
Email: Send Email [http://www.universalpressrelease.com/?pr=alfa-cytology-launches-huimmune-platform-to-facilitate-immunotherapy-candidate-screening-and-preclinical-studies]
Country: United States
Website: https://www.hu-immune.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.